Country: Canada
Language: English
Source: Health Canada
EVEROLIMUS
TEVA CANADA LIMITED
L04AH02
EVEROLIMUS
2.5MG
TABLET
EVEROLIMUS 2.5MG
ORAL
10
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0152682003; AHFS:
APPROVED
2019-12-06
_TEVA-EVEROLIMUS_ _ _ Page 1 of 102 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr TEVA-EVEROLIMUS Everolimus Tablets Tablets, 2.5 mg, 5 mg, 7.5 mg and 10 mg, Oral Protein Kinase Inhibitor ATC Code: L01XE10 Teva Canada Limited 30 Novopharm Court Toronto, ON M1B 2K9 Canada www.tevacanada.com Date of Initial Authorization: December 06, 2019 Date of Revision: MAR 06, 2024 Submission Control Number: 275710 _TEVA-EVEROLIMUS_ _ _ Page 2 of 102 RECENT MAJOR LABEL CHANGES 7 Warning and Precautions, Radiation Sensitization and Radiation Recall 03/2022 1 Indications, 1.1 Pediatrics 03/2022 3 Serious Warnings and Precautions Box 03/2022 4 Dosage and Administration, 4.1 Dosing Considerations 03/2022 4 Dosage and Administration, 4.4 Administration 03/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................ 2 TABLE OF CONTENTS ........................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................. 4 1 INDICATIONS .................................................................................................................... 4 1.1 Pediatrics ................................................................................................................... 5 1.2 Geriatrics .................................................................................................................... 6 2 CONTRAINDICATIONS ...................................................................................................... 6 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................. 6 4 DOSAGE AND ADMINISTRATION ...................................................................................... 7 4.1 Dosing Considerations ....................................... Read the complete document